Common Stock Purchase Agreement



 EXHIBIT 10.2 
  
 EXECUTION COPY 
  
 COMMON STOCK PURCHASE AGREEMENT 
  
                 This Common Stock Purchase Agreement (this
“Agreement”) is made and effective as of June 13, 2003 by and among Targeted Genetics Corporation, a Washington corporation (the “Company”), and the Purchasers identified in the signature pages attached hereto
(each, a “Purchaser” and, collectively, the “Purchasers”). 
  
                 WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to sell to the Purchasers
and the Purchasers severally desire to purchase from the Company certain shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), as more fully set forth in this Agreement. 
  
                 NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows: 
  
                 1.    Closing.

  
                 (a)    The closing of the sale of the securities contemplated hereby (the “Closing”) shall take place at
the offices of Proskauer Rose LLP, 1585 Broadway, New York, New York 10036, on June 17, 2003 or on such date or location as the parties shall otherwise agree. The date of the Closing is hereinafter referred to as the “Closing Date.”
At the Closing: (x) the Company shall issue and deliver to each Purchaser (i) a stock certificate, registered in the name of such Purchaser and free of all restrictive legends, representing the number of shares of Common Stock (the shares of Common
Stock issued and sold to the Purchasers hereunder are collectively, the “Shares”) equal to the quotient obtained by dividing (a) the purchase price set forth below such Purchaser’s signature to this Agreement by (b) $2.25, or,
for Purchasers who provide the necessary account information to the Company, the Company shall cause such shares to be issued and delivered into a balance account with The Depository Trust Company through its Deposit Withdrawal Agent Commission
System, (ii) a prospectus supplement (the “Supplement”) and base prospectus (the “Prospectus”) as contained in the Registration Statement (as defined in Section 3(g)) reflecting the sale of the Securities and
(iii) the legal opinion of the Company’s outside counsel containing the opinions substantially in the form set forth in the attached Exhibit A; and (y) each Purchaser shall deliver to the Company the purchase price set forth below such
Purchaser’s signature to this Agreement, in immediately available funds by wire transfer to an account designated in writing by the Company for such purpose. 
  
                 (b)    The obligation of the Purchasers to purchase and acquire Securities under this Agreement is subject to the
fulfillment (or waiver by such Purchaser) of each of the following conditions: 







 (i)    The Company shall have filed the Supplement with the
Securities and Exchange Commission (the “Commission”). 
  
 (ii)    The Registration Statement (as defined in Section 3(g) below) shall be effective on the Closing Date as to all Securities, not subject to any threatened or actual stop order and will not on
the Closing Date contain any untrue statement of material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. 
  
 (iii)    The Company shall have filed an additional shares listing application with the
NASDAQ Small Cap Market to cover the Securities. 
  
 (iv)    The Company shall have provided a certificate from a duly authorized officer certifying on behalf of the Company that each of the conditions set forth in this Section 1(b) shall have been satisfied. 

 
                 (c)    Notwithstanding anything to the contrary in this Section 1 and subject to Section 2 below, in the event that the
Company cannot deliver all of the items set forth in Sections 1(a) and 1(b) above, each Purchaser shall instead deliver the purchase price set forth in Section 1(a) to the Escrow Agent (the “Escrow Funds”), to be held by the Escrow
Agent in escrow on behalf of such Purchaser. Upon confirmation from all the Purchasers of receipt by the Purchasers of all the items set forth in Sections 1(a) and 1(b) above (which may be in writing or via email), the Escrow Agent shall release the
Escrow Funds to the Company. In the event all of the items set forth in Sections 1(a) and 1(b) are not delivered to a Purchaser on or prior to the Closing Date, the Escrow Agent shall immediately return the Escrow Funds to a Purchaser upon the
request of such Purchaser. The Escrow Agent hereby acknowledges and agrees to act as escrow agent in accordance with this Section 1(c). The Escrow Agent (i) shall be entitled to rely on any written or email communication received from a Purchaser
and (ii) shall not be liable for any acts or omissions of any kind any unless caused by its own gross negligence or willful misconduct. 
  
                 (d)    Definitions.    For the purposes of this Agreement, the following definitions shall apply:

  
 “Company Counsel” means Orrick, Herrington
& Sutcliffe LLP, counsel to the Company. 
  
 “Current
Reports” means (i) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2002, filed with the Commission on March 27, 2003, (ii) the Company’s Quarterly Report on Form 10-Q for the period ended March 31,
2003, filed with the Commission on May 15, 2003, and (iii) any reports on Form 8-K since May 15, 2003. 
  
 “Eligible Market” means any of the New York Stock Exchange, the American Stock Exchange, the NASDAQ Small Cap Market or the NASDAQ Small
Cap Market. 
  
 “Escrow Agent” means
Proskauer Rose LLP. 
  

 2 








 “Person” means any court or other federal, state, local or other governmental authority
or other individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

  
 “Securities” means the Shares issued or
issuable pursuant to this Agreement, together with any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. 
  
 “Transaction Documents” means this Agreement and any other
documents or agreements executed in connection with the transactions contemplated hereunder. 
  
 “Trading Day” means (a) any day on which the Common Stock is listed or quoted and traded on the NASDAQ Small-Cap Market, (b) if the Common Stock is not then listed or quoted and traded on any Eligible
Market, then a day on which trading occurs on the NASDAQ Small-Cap Market (or any successor thereto), or (c) if trading does not occur on the NASDAQ Small-Cap Market (or any successor thereto), any business day. 
  
         2.    Rights and Responsibilities of the Escrow Agent. Notwithstanding any other provision of this Agreement, in the event a dispute arises with regard
to any matter under this Agreement relating to the Escrow Funds, the following provisions shall apply. 
  
         (a)    If the Escrow Agent shall receive a written notice from a Purchaser or the
Company stating that a disagreement or dispute has arisen between the parties or any other persons resulting in adverse claims and demands being made with respect to the Escrow Funds (any such event being hereinafter referred to as a
“Dispute”), whether or not litigation has been instituted, then in any such event, the Escrow Agent shall continue to hold the Escrow Funds until the Escrow Agent receives either (i) a notice, signed by the party to such Dispute,
directing the delivery of the Escrow Funds; or (ii) a final non-appealable order of a court of competent jurisdiction, entered in an action, suit or proceeding in which the parties to the Dispute are parties, directing the delivery of the Escrow
Funds. In either of such events, the Escrow Agent shall then deliver the Escrow Funds in accordance with such direction. The Escrow Agent shall not be or become liable in any way or to any person for its refusal to comply with any such claims and
demands in the event of a Dispute unless and until it has received such direction. Upon compliance with such direction, the Escrow Agent shall be released of and from all liability and obligations hereunder. 
  
         (b)    Except for the Escrow Agent’s gross negligence or willful misconduct, the Escrow Agent shall not be responsible or liable in any manner whatsoever for the
sufficiency, correctness, genuineness or validity of any instrument deposited with it, or any notice or demand given to it or for the form of execution of any such instrument, notice or demand or for the identification, authority or rights of any
person executing, depositing or giving the same or for the terms and conditions of any instrument, pursuant to which the parties may act. 
  

 3 








         (c)    The Escrow Agent shall not
have any duties or responsibilities except those expressly set forth in Sections 1(c) and 2 of this Agreement and shall not incur any liability (i) in acting upon any signature, notice, demand, request, waiver, consent, receipt or other paper or
document believed by the Escrow Agent to be genuine and the Escrow Agent may assume that any person purporting to give it any notice on behalf of any party in accordance with the provisions hereof has been duly authorized to do so; or (ii) in
otherwise acting or failing to act under this Agreement except in the case of the Escrow Agent’s gross negligence or willful misconduct. 
  
         (d)    The terms and provisions of this Escrow arrangement shall create no right in
any person, firm or corporation other than the parties hereto and their respective successors and assigns and no third party shall have the right to enforce or benefit from the terms hereof. 
  
         (e)    The Escrow Agent shall not be bound by any modification, cancellation or rescission of this Agreement unless the same is in writing and signed by the Escrow Agent
and the other parties hereto. 
  
         (f)    The parties hereto, jointly and severally, shall indemnify the Escrow Agent from and against any and all losses, claims, damages or liabilities and expenses,
including reasonable attorney’s fees, which may be asserted against it or to which it may be exposed or may incur by reason of its performance hereunder, except to the extent caused by the Escrow Agent’s gross negligence or willful
misconduct. 
  
         (g)    The Company and the Purchasers acknowledge that the Escrow Agent has represented Mainfield Enterprises, Inc. in connection with this Agreement and may continue to
represent Mainfield Enterprises, Inc. in connection with the transactions contemplated pursuant to this Agreement, including, without limitation, in the event of disputes arising thereunder. The Company and Purchasers expressly agree that the Escrow
Agent shall not be precluded from or restricted in any manner whatsoever from representing Mainfield Enterprises, Inc. or otherwise acting as attorneys for Mainfield Enterprises, Inc. in any matter, including without limitation any court proceeding
or other matter related to this Agreement or the transactions contemplated hereby. The Company and Purchasers hereby irrevocably consent to any such representation and waive any conflict or appearance of conflict with respect thereto. 
  
         3.    Representations and Warranties of the Company. The Company hereby makes the following representations and warranties to each of the Purchasers:

  
         (a)    Subsidiaries. Except as disclosed in the Current Reports, the Company does not directly or indirectly control or own any interest in any other
corporation, partnership, joint venture or other business association or entity (a “Subsidiary”). Except as disclosed in the Current Reports, the Company owns, directly or indirectly, all of the capital stock of each Subsidiary free
and clear of any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction (collectively, “Liens”), and all the issued and outstanding shares of capital stock of each Subsidiary are validly
issued and are fully paid, non-assessable and free of preemptive and similar rights. 
  

 4 








         (b)    Organization and
Qualification. Each of the Company and the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization (as
applicable), with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to do business and is in good standing as a foreign corporation or other entity in each
jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could reasonably be expected to not,
individually or in the aggregate, (i) adversely affect the legality, validity or enforceability of any Transaction Document, (ii) have or result in a material adverse effect on the results of operations, assets, business or condition (financial or
otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) adversely impair the Company’s ability to perform fully on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material
Adverse Effect”). 
  
         (c)    Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents and otherwise to carry out its obligations hereunder. The execution and delivery of each Transaction Document by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly
authorized by all necessary action on the part of the Company and no further consent or action is required by the Company, its Board of Directors or its stockholders. Each of the Transaction Documents has been (or upon delivery will be) duly
executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms. 
  
         (d)    No Conflicts. The execution, delivery and performance of each Transaction Document by the Company and the consummation by the Company of the
transactions contemplated hereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii)
subject to obtaining the Required Approvals (as defined below), conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any
Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory organization to which the Company or its securities are
subject, or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not, individually or in the aggregate, have or result in a Material Adverse Effect.

  

 5 








         (e)    Filings, Consents and
Approvals. Neither the Company nor any Subsidiary is required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other
governmental authority or other Person in connection with the execution, delivery and performance by the Company of any Transaction Document, other than (i) the required filing of the Supplement, (ii) applicable Blue Sky filings, and (iii) in all
other cases where the failure to obtain such consent, waiver, authorization or order, or to give such notice or make such filing or registration could not have or result in, individually or in the aggregate, a Material Adverse Effect (collectively,
the “Required Approvals”). 
  
         (f)    Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the terms hereof, will be duly and
validly issued, fully paid and nonassessable, free and clear of all liens, encumbrances and rights of first refusal. The Company has reserved a sufficient number of duly authorized shares of Common Stock to issue all of the Securities. At the
Closing, the Securities shall have been listed for trading on the NASDAQ Small-Cap Market (the “Trading Market”). 
  
         (g)    Registration Statement. The Company’s Registration Statement
on Form S-3 (No. 333-74976) (the “Registration Statement”) was declared effective by the Commission on October 12, 2002. The Registration Statement is effective on the date hereof and the Company has not received notice that the
Commission has issued or intends to issue a stop order with respect to the Registration Statement or that the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or
intends or has threatened in writing to do so. The Registration Statement (including the information or documents incorporated by reference therein), as of the time it was declared effective, and any amendments or supplements thereto, each as of the
time of filing, did not contain any untrue statement of material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. The issuance of the Securities to the Purchasers is
registered by the Registration Statement. 
  
         (h)    Listing and Maintenance Requirements. Except as specified in the SEC Reports (as defined below), the Company has not, in the two years preceding the
date hereof, received notice from the Trading Market to the effect that the Company is not in compliance with the listing or maintenance requirements thereof. The Company is, and has no reason to believe that it will not in the foreseeable future
continue to be, in compliance with the listing and maintenance requirements for continued trading of the Common Stock on the Trading Market. 
  
         (i)    Certain Fees. Except for listing fees to be paid by the Company
to the Trading Market and placement agent fees payable to Roth Capital Partners, LLC, no fees or commissions will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees incurred by the Company or any other Person (other than the Purchasers, if the Purchasers have agreed
in writing to pay such fees) or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents. The
Company shall indemnify and hold harmless the Purchasers, their employees, officers, directors, agents, and partners, and their affiliates, from and against all claims, losses, damages, costs (including the reasonable costs of preparation and
reasonable attorney’s fees) and expenses suffered in respect of any such claimed or existing fees incurred by the Company or any other Person (other than the Purchasers, if the Purchasers have agreed in writing to pay such fees), as such fees
and expenses are incurred. 
  

 6 








         (j)    Disclosure. The
Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that constitutes or might constitute material, nonpublic information. The Company
understands and confirms that each of the Purchasers will rely on the foregoing representations in effecting transactions in securities of the Company. All disclosure provided to the Purchasers regarding the Company, its business and the
transactions contemplated hereby, including the Schedules to this Agreement, the Registration Statement, the Prospectus and the Supplement, furnished by or on behalf of the Company are true and correct and do not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. No event or circumstance has occurred or information exists with
respect to the Company or any of its Subsidiaries or its or their business, properties, prospects, operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but
which has not been so publicly announced or disclosed (assuming for this purpose that the Company’s reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are being incorporated into an
effective registration statement filed by the Company under the Securities Act of 1933, as amended (the “Securities Act”)). The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3. 
  
         (k)    No Violation. The issuance and sale of the Securities hereunder
does not conflict with or violate any rules or regulations of the Trading Market. 
  
         (l)    SEC Reports; Financial Statements. The Company has filed all reports required to be filed by it under the Exchange Act,
including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law to file such material) (the foregoing materials and any materials incorporated therein by
reference being collectively referred to herein as the “SEC Reports” and, together with this Agreement and the Schedules to this Agreement, the “Disclosure Materials”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the
Exchange Act and the rules and regulations of the Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with generally accepted accounting principles applied on a
consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto, and fairly present in all material respects the financial position of the Company and its
consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. All material
agreements to which the Company or any Subsidiary is a party or to which the property or assets of the Company or any Subsidiary are subject are included as part of or specifically identified in the SEC Reports. 
  

 7 








         (m)    Capitalization.
The authorized capital stock of the Company consists of 120,000,000 shares of common stock, of which 50,623,439 are issued and outstanding as of June 12, 2003, and 6,000,000 shares of preferred stock, of which all outstanding shares of capital stock
are duly authorized, validly issued, fully paid and nonassessable and have been issued in compliance with all applicable securities laws. Except as disclosed in the Current Reports, there are no outstanding options, warrants, script rights to
subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or
contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock, or securities or rights convertible or exchangeable into shares of Common Stock. Except
as disclosed in the Current Reports, there are no anti-dilution or price adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security holders) and the issue and sale of the Securities will
not obligate the Company to issue shares of Common Stock or other securities to any Person and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under such securities. To the
knowledge of the Company, except as disclosed in the Current Reports, no Person or group of related Persons beneficially owns (as determined pursuant to Rule 13d-3 under the Exchange Act), or has the right to acquire, by agreement with or by
obligation binding upon the Company, beneficial ownership of in excess of 5% of the outstanding Common Stock, ignoring for such purposes any limitation on the number of shares of Common Stock that may be owned at any single time. 
  
         (n)    Material Changes. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in the
SEC Reports, (i) there has been no event, occurrence or development that, individually or in the aggregate, has had or that could result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other
than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or required to be
disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting or the identity of its auditors, except as disclosed in its SEC Reports, (iv) the Company has not declared or made any dividend or distribution
of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except
pursuant to existing Company stock-based plans. 
  
         (o)    Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in
the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company or any other
Purchaser (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with this Agreement and the
transactions contemplated hereby is merely incidental to such Purchaser’s purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement has been based solely on the
independent evaluation of the Company and its representatives. 
  

 8 








         4.    Representations
and Warranties of the Purchasers. Each Purchaser hereby for itself and for no other Purchaser, represents, warrants and covenants to the Company that each such Purchaser is an entity is duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation. Such Purchaser has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize
the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement and assuming the valid execution hereof by the Company, this Agreement shall constitute the valid and binding obligation of such Purchaser
enforceable in accordance with its terms. Such Purchaser is a resident of that jurisdiction specified next to the heading “Residence” on the signature page hereto. The Company acknowledges and agrees that no Purchaser makes or has made any
representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Section 4. 
  
         5.    Other Agreements of the Parties. 
  
 5.1    Lock-up 
  
         (a)    Except for the issuance of Common Stock pursuant to Section 1(b), from the date hereof through July 14, 2003 (including such date) (the “Blockout
Period”), the Company will not, directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or the
Subsidiaries’ equity or equity equivalent securities, including without limitation any debt, preferred stock or other instrument or security that is, at any time during its life and under any circumstances, convertible into or exchangeable or
exercisable for Common Stock or Common Stock Equivalents. 
  
         (b)    The restrictions contained in paragraph (a) of this Section shall not apply to (i) the granting of options to employees, officers and directors of the Company
pursuant to any stock option plan duly adopted by the Company or to the issuance of Common Stock upon exercise of such options, or (ii) transactions with entities with which the Company has pre-existing business relationships, other than financial
relationships, or such other entities whose primary business is the development, delivery and marketing of pharmaceutical products. 
  
 5.2    Disclosure of Material Non-Public Information. The Company confirms that the Company has not and shall not, and the
Company shall cause each of its Affiliates (as defined in Rule 405 under the Securities Act) and other Persons acting on its behalf not to, divulge to any Purchaser any information that it believes to be material non-public information unless such
Purchaser has agreed in writing to receive such information prior to such divulgence. Each Purchaser has made its own independent examination, investigation, analysis and evaluation of the Company, including but not limited to an evaluation of the
value of the Securities and has not relied upon any non-public information relating to the Company provided to the Purchasers by the Company or any of its Affiliates or other persons acting on its behalf. 
  

 9 








 5.3    Listing of Securities. The Company shall take such steps as may be
required to cause and maintain the listing of the Securities on the Trading Market and such other exchange, market or quotation facility on which the Common Stock is traded. 
  
 5.4    Indemnification 
  
         (a)    The Company will indemnify and hold harmless each
Purchaser and any of its affiliates or any officer, director, partner, controlling person, employee or agent of a Purchaser or any of its affiliates (a “Related Person”) for its reasonable legal and other expenses (including the
costs of any investigation, preparation and travel) and for any Losses incurred in connection with any action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a disposition),
whether commenced or threatened (each, a “Proceeding”), insofar as such Losses arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, the
Prospectus or the Supplement, or any amendment or supplement thereto, and all other documents filed as a part thereof, as amended at the time of effectiveness of the Registration Statement, including any information deemed to be a part thereof as of
the time of effectiveness pursuant to paragraph (b) of Rule 430A, or pursuant to Rule 434, under the Securities Act, or arise out of or are based upon the omission or alleged omission to state in any of them a material fact required to be stated
therein or necessary to make the statements in any of them (in the case of the Prospectus and the Supplement only, in light of the circumstances under which they were made) not misleading, as such expenses or Losses are incurred. In addition, the
Company shall indemnify and hold harmless each Purchaser and Related Person from and against any and all Losses, as incurred, arising out of or relating to any breach by the Company of any of the representations, warranties or covenants made by the
Company in this Agreement or any other Transaction Document, or any allegation by a third party that, if true, would constitute such a breach. The conduct of any Proceeding for which indemnification is available under this paragraph shall be
governed by Section 5.4(b). The indemnification obligations of the Company under this paragraph shall be in addition to any liability that the Company may otherwise have and shall be binding upon and inure to the benefit of any successors, assigns,
heirs and personal representatives of the Purchasers and any such Related Persons. The Company also agrees that neither the Purchasers nor any Related Persons shall have any liability to the Company or any Person asserting claims on behalf of or in
right of the Company in connection with or as a result of the transactions contemplated by the Transaction Documents, except to the extent that any losses, claims, damages, liabilities or expenses incurred by the Company result from the gross
negligence or willful misconduct of the applicable Purchaser or Related Person in connection with such transactions. If the Company breaches its obligations under any Transaction Document, then, in addition to any other liabilities the Company may
have under the Transaction Documents or applicable law, the Company shall pay or reimburse the Purchasers on demand for all costs of collection and enforcement (including reasonable attorneys fees and expenses). Without limiting the generality of
the foregoing, the Company specifically agrees to reimburse the Purchasers on demand for all costs of enforcing the indemnification obligations in this paragraph. For the purposes of this Section 5.4, “Losses” shall mean any and all
losses, claims, damages, liabilities, settlement costs and expenses, including without limitation costs of preparation of legal action and reasonable attorneys’ fees. 
  

 10 








         (b)    Conduct of Indemnification
Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the
“Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and
expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to the Transaction Documents, except
(and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the
Indemnifying Party. 
  
         An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Party or Parties unless: (i) the Indemnifying Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ
counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such
Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the
Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the
Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written
consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such Proceeding. 
  
         All fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a
manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that an Indemnified Party
is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party
is not entitled to indemnification hereunder). 
  

 11 








 5.5    Registration Statement 
  
                 (a)    In addition to other remedies available to a Purchaser hereunder and under law, in the event the Registration
Statement is not effective on the date hereof and on the Closing Date, then, a Purchaser shall have the right to rescind the transactions contemplated by this Agreement. 
  
         6.    Miscellaneous  
  
         (a)    Fees and Expenses. At the Closing, the Company shall pay to Mainfield Enterprises, Inc. an aggregate of $20,000 for their legal fees and expenses incurred in
connection with its due diligence and the preparation and negotiation of this Agreement. In lieu of the foregoing payment, Mainfield Enterprises, Inc. may retain such amount at the Closing or require the Company to pay such amount directly to
Proskauer Rose LLP. Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of their applicable
Securities. 
  
         (b)    Securities Laws Disclosure; Publicity. The Company shall, on or before 9:30 a.m., Eastern Standard time, on June 13, 2003, issue a press release reasonably
acceptable to the Purchasers disclosing all material terms of the transactions contemplated hereby and file a Form 8-K with the Commission (the “8-K Filing”) describing the terms of the transactions contemplated by this Agreement
and including as exhibits to such 8-K Filing this Agreement, in the form required by the Exchange Act. Thereafter, the Company shall timely file any filings and notices required by the Commission or applicable law with respect to the transactions
contemplated hereby and provide copies thereof to the Purchasers promptly after filing. Neither the Company nor the Purchasers shall issue any press release or make any other public announcement relating to this Agreement unless (i) the content
thereof is mutually agreed to by the Company and the Purchasers, or (ii) such party is advised by its counsel that such press release or public announcement is required by law; except that no press release issued to disclose the issuance and sale of
the Securities to the Purchasers will refer to the Purchasers by name. Each press release disseminated during the three years preceding the date of this Agreement did not at the time of release contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading. 
  
         (c)    Entire Agreement; Amendments. This
Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been
merged into this Agreement and its exhibits and schedules. This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and Purchasers then holding two-thirds of the Shares purchased hereunder. The
waiver by either party hereto of any right hereunder or the failure to perform or of a breach by the other party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar
nature or otherwise. 
  

 12 








         (d)    Notices. Any and all
notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number specified in this Section prior to 6:30 p.m. (New York City time) on a Trading Day, (ii) the Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in this Agreement later than 6:30 p.m. (New York City time) on any date and earlier than 11:59 p.m. (New York City time) on such date, (iii) the Trading Day following the date of mailing, if sent by nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows: 
  

	 If to the Company:
	  	 Targeted Genetics Corporation
 1100 Olive
Way, Suite 100
 Seattle, WA 98101
 Facsimile No.: (206)
623-7064
 Attn: Chief Financial Officer

		
	 With a copy to:
	  	 Orrick, Herrington & Sutcliffe LLP
 719 Second Avenue East, Suite 900
 Seattle, WA 98104
 Facsimile No.: (206) 839-4301
 Attn: Stephen M. Graham

		
	 If to the Purchasers:
	  	To the address set forth under such Purchaser’s name on the signature pages attached hereto.

  
         or such other address as may be designated in writing hereafter, in the same manner, by such Person. 
  
         (e)    Governing Law. All questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all
legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or
agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the
City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of this Agreement), and
hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper. Each party hereto hereby
irrevocably waives personal service 
  

 13 








 of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right
to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys fees and other reasonable costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

  
         (f)    Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original thereof.

  
         (g)    Independent Nature of Purchasers. The obligations of each Purchaser under this Agreement are several and not joint with the obligations of any other
Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under this Agreement. The decision of each Purchaser to purchase Securities pursuant to this Agreement has been made by such
Purchaser independently of any other Purchaser and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or
otherwise) or prospects of the Company or of the Subsidiary which may have been made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no Purchaser or any of its agents or employees shall have any liability to
any other Purchaser (or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein, and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by
this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an
additional party in any proceeding for such purpose. 
  
     (h)    Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this
Agreement or any rights or obligations hereunder without the prior written consent of the Purchaser. The Purchaser may assign its rights under this Agreement to any Person. 
  

 14 








         (i)    Adjustments in Share
Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly
shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference in the Transaction Documents to a number of shares or a price per share shall be amended to appropriately account for
such event. 
  
         (j)    Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or
cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft
or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement
Securities. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

 SIGNATURE PAGES FOLLOW] 
  
  

 15 








 IN WITNESS WHEREOF, the parties hereto have caused this Common Stock Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

	TARGETED GENETICS CORPORATION
		
	 By:
	 	    /s/ TODD E. SIMPSON
	 	 	

	 	 	Name: Todd E. Simpson
	 	 	Title: Chief Financial Officer


  
 [REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK 
 SIGNATURE PAGE OF PURCHASERS FOLLOWS] 
  
  

 16 








 IN WITNESS WHEREOF, the parties hereto have caused this Common Stock Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

	 	 	MAINFIELD ENTERPRISES, INC.
			
	 	 	 By:
	 	    /s/    AVI VIGDER
	 	 	 	 	

	 	 	 	 	 Name: Avi Vigder

	 	 	 	 	 Title: Authorized Signatory

		
	 	 	Purchase Price:
                                  $5,374,998
		
	 	 	Number of Shares to be acquired:     2,388,888
		
	 	 	 Residence:
  

	 	 	Address for Notice:
	 	 	Mainfield Enterprise, Inc.
	 	 	c/o Eldad Gal
	 	 	600 Madison Avenue
	 	 	New York, NY 10022
	 	 	Telephone No.: (212) 651-9000
	 	 	 Facsimile No.: (212) 651-9010
  

	With copies to:	 	Proskauer Rose LLP
	 	 	1585 Broadway
	 	 	New York, NY 10036-8299
	 	 	Facsimile No.: (212) 969-2900
	 	 	Attn: Adam J. Kansler, Esq.


  








	CRANSHIRE CAPITAL, L.P
		
	 By:
	 	     /s/    MITCHELL P.
KOPIN        


	 	 	Name: Mitchell P. Kopin
	 	 	Title: President-Downsview Capital
	 	 	 



	Purchase Price:	 	 $3,375,000
  

	 Number of Shares to be acquired:
	 	1,500,000
		
	 Residence:
  
	 	 
	 Address for Notice:
 Cranshire Capital,
L.P.
 666 Dundee Road, Suite 1901
 Northbrook, IL
60062
 Facsimile No.: (847) 562-9031
 Telephone No.: (847)
562-9030
 Attn: Mitchell Kopin
	 	 


  
  
  
  
  
  

 18 








  
  

	SMITHFIELD FIDUCIARY LLC
		
	 By:
	 	     /s/    ADAM J.
CHILL            


	 	 	 Name: Adam J. Chill
 Title: Authorized
Signatory




		
	 Purchase Price:
	 	 $4,375,001.25
  

	 Number of Shares to be acquired:
	 	 1,944,445
  

	 Residence: Cayman Islands
	 	 
	
	 Address for Notice:

	 Smithfield Fiduciary LLC
 c/o
Highbridge Capital Management, LLC
 9 West 57th Street, 27th Floor
 New York, New York 10019
 Facsimile No.:(212) 751-0755
 Telephone No.:(212) 287-4720
 Attn: Ari J. Storch / Adam J. Chill



  
  
  
  

 19 









	PORTSIDE GROWTH & OPPORTUNITY FUND
		
	 By:
	 	     /s/    JEFFREY M.
SOLOMON        


	 	 	Name: Jeffrey M. Solomon
	 	 	 Title: Partner
  




	Purchase Price:	 	$4,375,001.25
		
	Number of Shares to be acquired:	 	 1,944,445
  

	 Residence: Cayman Islands
  
	 	 
	 Address for Notice:
 c/o Ramius Capital
Group, L.L.C.
 666 Third Avenue, 26th Floor
 New York, NY
10017
 Facsimile: (212) 845-7999
 Telephone: (212)
845-7917
 Attn: Jeffrey M. Solomon
          Jeffrey Smith
	 	 


  

 20